Clinical Trials Directory

Trials / Unknown

UnknownNCT01471301

Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Federal University of São Paulo · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate ultrasound hands in patients with systemic lupus erythematosus.

Detailed description

Introduction: The systemic lupus erythematosus (SLE) is a disease with a common articular involvement. Approximately 1-2% of patients with SLE have joint inflammation similar to rheumatoid arthritis (RA). There are no well-designed studies of lupus arthropathy. Primary objectives: To evaluate the ultrasonographic examination of the hands in patients with systemic lupus erythematosus and make its correlation with examination of patients with rheumatoid arthritis (RA) established and with clinical, serological, radiological and functional. Material and methods: a transversal study will be carried out on patients diagnosed with with SLE and RA. Clinical Instruments: count of swollen and tender joints, visual analogue scale (VAS) for pain (0-10 cm), edema and for disease activity; disease activity (DAS 28 and SLEDAI), hand grip strength and pinch (Jamar dynamometer and Preston Pinch Gauge); functional questionnaires (HAQ and DASH). It will be observed the presence of "puffy hands", Raynaud's phenomenon and presence of autoantibodies. Radiographic instruments: evaluation of radiographs of hands and wrists according to the Sharp score modified by van der Heijde. Ultrasonographic Instruments (quantitative and semi-quantitative measures): synovial hyperplasia, synovial blood flow (Power Doppler), bone erosions and cartilage. The joints that will be evaluated: radiocarpal, distal radioulnar, first to fifth metacarpophalangeal and proximal interphalangeal. Ultrasonographic interobserver reproducibility will be carried out in 10% of the patients. All the examinators will be blind for each other findings. Rheumatoid factor and anti-CCP will be investigated in RA patients. Statistical significance will be set at 5%.

Conditions

Timeline

Start date
2011-06-01
Primary completion
2011-11-01
First posted
2011-11-15
Last updated
2011-11-15

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01471301. Inclusion in this directory is not an endorsement.